http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 06:58:45 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Jazz+Pharmaceuticals+%28JAZZ%29/27008547.html <p>Canaccord analyst Gary Newman reiterated a Buy rating and $300.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).</p><p>The analyst commented: "The second interim topline OS result from the HERIZON-GEA-01 Phase 3 demonstrated that Ziihera plus chemotherapy had a statistically significant and clinically meaningful OS benefit vs. trastuzumab plus chemotherapy in 1L GEA. This follows last week's approval of Ziihera in combination with tislelizumab and chemo (HER2+ IHC 3+ and IHC 2+/ISH+) and Ziihera plus chemo alone (HER2+ IHC 3+) for 1L GEA. Notably, the primary distinction between the two interim analyses (first was announced 11/17/25) is that in this latest one http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Jazz+Pharmaceuticals+%28JAZZ%29/27008547.html Tue, 01 Sep 2026 06:58:45 -0400 JAZZ http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+Iannone+Robert/26990517.html si-local-file:///var/storage/secattach/20260827/26990517.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+Iannone+Robert/26990517.html Thu, 27 Aug 2026 16:31:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+Iannone+Robert/26990517.html si-local-file:///var/storage/secattach/20260827/26990517.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Jazz+Pharmaceuticals+++++++++++++++++++Filed+by%3A+Iannone+Robert/26990517.html Thu, 27 Aug 2026 16:31:00 -0400 JAZZ O.12498162 http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Corporate+News/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html <p>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has priced a $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, upsized from an initially announced $1.0 billion, according to a press release. The notes are being issued through Jazz Investments I Limited, a wholly-owned subsidiary.</p> <p>The offering is expected to close on August 31, 2026, subject to customary conditions. Initial purchasers were also granted the option to buy up to an additional $150.0 million in aggregate principal amount within 13 days of the initial issue date. Estimated net proceeds are approximately $1,079.0 million, or approximately $1,226.4 million if the overallotment option is http://www.streetinsider.com/Stock+Buybacks/Jazz+Pharmaceuticals+prices+%241.1B+exchangeable+notes+offering+due+2032/26983400.html Thu, 27 Aug 2026 00:30:20 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/Press+Releases/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ie..dublin" idsrc="xmltag.org" >DUBLIN</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals plc</span> (Nasdaq: JAZZ) ("<span value="NASDAQ-NMS:JAZZ" idsrc="xmltag.org" >Jazz Pharmaceuticals</span>") announced the pricing of <money>$1.1 billion</money> aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by <span value="ACORN:5020191690" idsrc="xmltag.org" >Jazz Investments I Limited</span>, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of <money>$1.0 billion</money> aggregate principal amount of notes. The Issuer http://www.streetinsider.com/PRNewswire/Jazz+Pharmaceuticals+Announces+Pricing+of+Upsized+Private+Offering+of+%241.1+Billion+of+1.875%25+Exchangeable+Senior+Notes+due+2032+and+Concurrent+Ordinary+Share+Repurchases/26983399.html Thu, 27 Aug 2026 00:30:00 -0400 A.50201916 JAZZ O.12498162 O.26306456 http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24281+at+Truist+Securities/26977125.html (Updated - August 26, 2026 9:36 AM EDT) <p>Truist Securities analyst Gregory Renza raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $281.00 (from $264.00) while maintaining a Buy rating.</p><p>The analyst commented: "GEA Approval Sets-Up New Conviction, Climbing Peak Potential from Ziihera Franchise; JAZZ hosted a call on Ziihera's 1L HER2+ GEA approval underscoring a notable conviction on the foundational asset potential for zanidatamab, where the new nod now carves a path for even greater peak revenue prospects & expansion. While, to us, the GEA label arrived inline, with both regimens carrying an OS win vs. trastuzumab + chemo, DoR http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24281+at+Truist+Securities/26977125.html Wed, 26 Aug 2026 09:36:23 -0400 JAZZ http://www.streetinsider.com/Analyst+Comments/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24281+at+Truist+Securities/26977125.html (Updated - August 26, 2026 9:36 AM EDT) <p>Truist Securities analyst Gregory Renza raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $281.00 (from $264.00) while maintaining a Buy rating.</p><p>The analyst commented: "GEA Approval Sets-Up New Conviction, Climbing Peak Potential from Ziihera Franchise; JAZZ hosted a call on Ziihera's 1L HER2+ GEA approval underscoring a notable conviction on the foundational asset potential for zanidatamab, where the new nod now carves a path for even greater peak revenue prospects & expansion. While, to us, the GEA label arrived inline, with both regimens carrying an OS win vs. trastuzumab + chemo, DoR http://www.streetinsider.com/Analyst+Comments/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24281+at+Truist+Securities/26977125.html Wed, 26 Aug 2026 09:36:23 -0400 JAZZ http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24277+at+RBC+Capital/26978049.html <p>RBC Capital analyst Leonid Timashev raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $277.00 (from $273.00) while maintaining an Outperform rating.</p><p>The analyst commented: "We think the label is favorable for JAZZ. While largely expected, we think today's approval of both the doublet and triplet regimen is an important win for JAZZ - and shifting the PoS in our model to 100% brings our price target to $277. While there may be some debate over the exclusion of IHC 2+/ISH+ in the doublet (we think an incremental loss of 15% of pts, who are still eligible for the triplet http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24277+at+RBC+Capital/26978049.html Wed, 26 Aug 2026 09:00:27 -0400 JAZZ http://www.streetinsider.com/Analyst+Comments/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24277+at+RBC+Capital/26978049.html <p>RBC Capital analyst Leonid Timashev raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $277.00 (from $273.00) while maintaining an Outperform rating.</p><p>The analyst commented: "We think the label is favorable for JAZZ. While largely expected, we think today's approval of both the doublet and triplet regimen is an important win for JAZZ - and shifting the PoS in our model to 100% brings our price target to $277. While there may be some debate over the exclusion of IHC 2+/ISH+ in the doublet (we think an incremental loss of 15% of pts, who are still eligible for the triplet http://www.streetinsider.com/Analyst+Comments/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24277+at+RBC+Capital/26978049.html Wed, 26 Aug 2026 09:00:27 -0400 JAZZ http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24322+at+Morgan+Stanley/26977641.html Morgan Stanley analyst Jeffrey Hung raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $322.00 (from $283.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24322+at+Morgan+Stanley/26977641.html Wed, 26 Aug 2026 08:16:09 -0400 JAZZ http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24310+at+Needham/26977261.html (Updated - August 26, 2026 7:14 AM EDT) <p>Needham analyst Ami Fadia raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $310.00 (from $292.00) while maintaining a Buy rating.</p><p>The analyst commented: "JAZZ management held an investor call yesterday post-approval of Ziihera in 1L HER2+ GEA patients. The triplet combo with tislelizumab and chemo is expected to become the SoC based on the strong survival plus broad label (includes both IHC3+ and IHC 2+/ISH+). The launch dynamics are expected to be smooth given the strong overlap between BTC and GEA with initial focus on the community setting (~70% of GEA patients). http://www.streetinsider.com/Analyst+PT+Change/Jazz+Pharmaceuticals+%28JAZZ%29+PT+Raised+to+%24310+at+Needham/26977261.html Wed, 26 Aug 2026 07:14:12 -0400 JAZZ